These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35395636)

  • 21. Diffuse intrinsic pontine gliomas in adults: A retrospective study.
    Kandregula S; Konar S; Sadashiva N; Nagesh M; Kalahasti SR; Krishna U; Saini J; Shukla D; Santosh V
    Neurol India; 2022; 70(2):584-590. PubMed ID: 35532623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry.
    Veldhuijzen van Zanten SEM; Lane A; Heymans MW; Baugh J; Chaney B; Hoffman LM; Doughman R; Jansen MHA; Sanchez E; Vandertop WP; Kaspers GJL; van Vuurden DG; Fouladi M; Jones BV; Leach J
    J Neurooncol; 2017 Aug; 134(1):231-240. PubMed ID: 28560664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
    Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
    Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multimodal imaging-based classification for pediatric diffuse intrinsic pontine gliomas.
    Pan C; Zhang M; Xiao X; Kong L; Wu Y; Zhao X; Sun T; Zhang P; Geng Y; Zuo P; Wang Y; Li X; Gu G; Li T; Wu Z; Zhang J; Zhang L
    Neurosurg Rev; 2023 Jun; 46(1):151. PubMed ID: 37358632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving long-term survival in diffuse intrinsic pontine glioma.
    Felker J; Broniscer A
    Expert Rev Neurother; 2020 Jul; 20(7):647-658. PubMed ID: 32543245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study.
    Kim HJ; Lee JH; Kim Y; Lim DH; Park SH; Ahn SD; Kim IA; Im JH; Chung JW; Kim JY; Kim IH; Yoon HI; Suh CO
    Cancer Res Treat; 2023 Jan; 55(1):41-49. PubMed ID: 35255651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma.
    Yamasaki F; Nishibuchi I; Karakawa S; Kaichi Y; Kolakshyapati M; Takano M; Yonezawa U; Imano N; Taguchi A; Shimomura M; Taniguchi M; Onishi S; Okada S; Awai K; Sugiyama K; Nagata Y
    Pediatr Neurosurg; 2021; 56(1):1-9. PubMed ID: 33535215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry.
    Leach JL; Roebker J; Schafer A; Baugh J; Chaney B; Fuller C; Fouladi M; Lane A; Doughman R; Drissi R; DeWire-Schottmiller M; Ziegler DS; Minturn JE; Hansford JR; Wang SS; Monje-Deisseroth M; Fisher PG; Gottardo NG; Dholaria H; Packer R; Warren K; Leary SES; Goldman S; Bartels U; Hawkins C; Jones BV
    Neuro Oncol; 2020 Nov; 22(11):1647-1657. PubMed ID: 32506137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
    Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
    Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature.
    Dimentberg E; Marceau MP; Lachance A; Bergeron-Gravel S; Saikali S; Crevier L; Bourget C; Hawkins C; Jabado N; Giannakouros P; Renzi S; Larouche V
    J Pediatr Hematol Oncol; 2024 May; 46(4):211-215. PubMed ID: 38573000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric diffuse intrinsic pontine glioma: where do we stand?
    Rashed WM; Maher E; Adel M; Saber O; Zaghloul MS
    Cancer Metastasis Rev; 2019 Dec; 38(4):759-770. PubMed ID: 31802357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased natural killer cells in diffuse intrinsic pontine glioma patients.
    Zhang L; Yu H; Xue Y; Liu Y
    Childs Nerv Syst; 2020 Jul; 36(7):1345-1346. PubMed ID: 32418048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.